Today, cardiovascular disease has become the number one killer of humans. On September 17, 2015, the 15th World Congress of Arrhythmia was held at the Beijing National Convention Center. One of the authoritative experts said: "Today, the proportion of reimbursement for cardiovascular stents is about 70%. However, some medical devices that can prevent sudden cardiac death are only reimbursed for about 30%. The gap is still quite large. It should be selected and promoted as soon as possible. It is suitable for the arrhythmia diagnosis and treatment equipment of patients in China, and improves the prevention and treatment level of arrhythmia in China." There is a gap between treatment and demand Experts at home and abroad conducted in-depth exchanges on the prevention and treatment of arrhythmia and technological progress at this conference. Professor Panos E. Vardas, president of the World Arrhythmia Society, said: "Heavy cardiac death is a very high-risk fatal disease and the number one life killer of cardiovascular disease patients worldwide. Over the past 40 years, global cardiovascular medicine has made remarkable progress. The average life expectancy of patients with vascular disease has been extended by more than 10 years. In contrast, the huge oncology of medicine has only extended the average life expectancy of cancer patients by about 6 months." Professor Huang Congxin, director of the Institute of Cardiovascular Diseases of Wuhan University, objectively analyzed the prevention and treatment of arrhythmia in China. He said that in recent years, the development of arrhythmia prevention and treatment in China is in good shape, but there is still a clear gap compared with the actual medical treatment needs and the prevention and control level of developed countries in Europe and America. There are about 20 million patients with arrhythmia in China, and 540,000 sudden cardiac deaths occur each year. In 2014, there were about 170,000 arrhythmia treatments in China, including 60,000 pacemaker treatments, 25,000 atrial fibrillation catheter ablation, and more than 2,000 cardiac defibrillators (ICDs). Compared with the newly released 540,000 cases of sudden cardiac death, the prevention and treatment is still insufficient. Promote technology and encourage innovation According to reports, arrhythmia is the most important cause of sudden cardiac death. Out-of-hospital first-aid and clinical treatment of arrhythmia relies to a large extent on some sophisticated medical devices, and even some medical devices are more effective than drug treatment. Among them, the automatic defibrillator (AED) is a portable medical device for the rescue of patients with sudden cardiac death. Non-professionals can also use it. Its popularity can greatly improve the success rate of out-of-hospital first aid. “The key is to establish a first-aid system for sudden cardiac death outside the hospital and in the community. There is a good news recently – Shanghai has to be equipped with AEDs in public places.†Professor Huang Dejia said that the emergency success rate of out-of-hospital hospitals in Seattle, USA is more than 10%; and the survival rate of out-of-hospital emergency in China's sudden cardiac death is only about 1%. He believes that the establishment of an emergency system outside the hospital requires the joint efforts of government departments, social organizations, and medical personnel. Government departments and social organizations should bear more of the necessary responsibilities. Academic organizations and medical personnel should vigorously carry out education and training for the public and medical personnel. "A large number of studies have shown that ICD treatment can effectively avoid sudden death caused by ventricular arrhythmia, but the lack of cognitive, technical and investment limits the promotion of ICD treatment technology in China." Professor Zhang Wei, director of the Arrhythmia Center of Fuwai Hospital of Chinese Academy of Medical Sciences, pointed out that the general population and even medical staff in China have insufficient knowledge of the existing mature and effective arrhythmia diagnosis and treatment techniques. Nowadays, hospitals and doctors who can carry out ICD treatment technology in China are very limited. ICD products have not yet been domestically produced, and imported products cost more than 100,000 yuan. The medical insurance system did not fully cover this treatment, lacked commercial insurance investment, and did not establish an installment payment mechanism. Expensive imported devices are very burdensome for the average person. Zhang Wei also pointed out that the independent innovation of medical concepts and technical products in China is still relatively rare. It is necessary to find suitable technologies suitable for popularization in China as soon as possible in many arrhythmia diagnosis and treatment technologies, and transform innovative management models to encourage doctors to participate in medical devices. Research and development to achieve localization of related medical devices and expand accessibility. Nowadays, the first-aid knowledge of cardiovascular disease and the use of related medical devices should be popularized. At the same time, we will vigorously develop medical equipment related to cardiovascular diseases in China. Let patients get treatment in the first time and reduce mortality.
10:1 Milk Thistle Powder Milk Thistle Extract is a kind of Milk Thistle Extract and the Key Product of our company. It is a light yellow powder which is extracted, concentrated and dried from the stems and leaves of milk thistle. Milk Thistle Extract,Milk Thistle Extract Liquid,Milk Thistle Extract Powder,Milk Thistle Extract Silymarin Shaanxi Kepler Biotech Co.,Ltd , https://www.keplerherb.com
Milk Thistle is an annual or biennial herb, native to southern Europe and north Africa, and has been cultivated and used for thousands of years in Europe and Africa, and is a folk medicinal plant. Milk Thistle is widely used as a treatment for liver disease and cardiovascular disease.
Milk Thistle is a yearly or biennial plant herbaceous plant, for plant1-2 years herbaceous plant.To mature seeds for medicinal use, there are antipyretic detoxification, liver protection, gallbladder, brain protection and anti-X ray function;Clinical indications acute hepatitis, chronic hepatitis, cirrhosis, fatty liver, metabolic toxic liver injury, cholelithiasis, etc.
Milk thistle high medicinal value, wide application, our country many pharmaceutical factory, plant extraction plant all kinds of products have been taking milk thistle as the main raw material to produce a market at home and abroad, the sales volume increased, prices WenZhongQuSheng, part of the bravery liver protection and Milk Thistle ,Milk Thistle capsule, bean milk thistle capsules and other proprietary Chinese medicine has become a hot stock market;Seeds and whole grass can be used as medicine.Milk Thistle can clear away heat and detoxify, protect liver and protect liver and resist X ray. It is used for the treatment of acute and chronic hepatitis, cirrhosis, liver poisoning, Cholelithiasis, etc. In recent years, China's science has found that Milk Thistle also has the functions of lowering blood lipid, protecting myocardium, dilating blood vessels, resisting radiation, anti-platelet and anti-gastric ulcer.